Stay updated with breaking news from Progressive Multiple Sclerosis Expected. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Preclinical Data Published in the Journal of Medicinal Chemistry Identifies Vidofludimus Calcium as a Potent Nurr1 Activator, Reinforcing Neuroprotective...
– Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease Provide Proof-of-Concept for a New Therapeutic Approach to Treat Gastrointestinal...
Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update Positive Results From Phase 1b Clinical... | May 11, 2023
/PRNewswire/ -- Immunic, Inc. (NASDAQ: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...